AAREYDRUGS · NSE
Aarey Drugs & Pharmaceuticals Limited
₹102.52
+0.15% (+₹0.15)
Prev. close
₹102.37
Volume
2,81,824
Delivery %
58.5%
As of
22 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company offers intermediates, including mono methyl urea, di methyl urea, ortho para nitro anisole, 2-bromomethyl-1,3-dioxolane, and uracil. It also provides active pharmaceutical ingredients, such as metformin HCl, mefenamic acid, and doxofylline. In addition, the company trades chemicals and solvents, including aromatic chemicals, chemical acids, chlor-alkali, glycols and glycol ethers, fiber intermediates, and acetates and esters, as well as industrial alcohols, ketones, amines, oleochemicals, intermediates, olefins, phosphates, fertilizers, monomers, and chemicals. It serves pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. Aarey Drugs & Pharmaceuticals Limited was incorporated in 1990 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Mihir Rajesh Ghatalia B.E
Headquarters
Mumbai
Website
aareydrugs.comExchange
View on NSE ↗Key stats
Market cap
₹337.55 Cr
P/E ratio (TTM)
78.4
EPS (TTM)
₹1.29
Beta (1Y · daily vs NIFTY 50)
1.34
Beta (5Y · monthly vs NIFTY 50)
2.51
Shares float
1.32 Cr
EPS · quarter ended Jun 2026
₹0.36
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. Net income and EBITDA are omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹492.68 Cr | ₹412.85 Cr | ₹395.62 Cr | ₹473.94 Cr | ₹472.27 Cr | |
| EBITDA | — | ₹14.02 Cr | ₹10.19 Cr | ₹11.42 Cr | ₹11.93 Cr | ₹13.27 Cr |
| — | ₹7.53 Cr | ₹3.77 Cr | ₹4.68 Cr | ₹4.02 Cr | ₹3.97 Cr | |
| Diluted EPS | — | ₹2.72 | ₹1.49 | ₹1.84 | ₹1.41 | ₹1.39 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹233.04 Cr | ₹245.17 Cr | ₹291.00 Cr | ₹303.00 Cr | ₹291.00 Cr | ₹297.00 Cr | |
| ₹18.02 Cr | ₹14.16 Cr | ₹37.72 Cr | ₹31.35 Cr | ₹34.86 Cr | ₹49.96 Cr | |
| Stockholders' equity | ₹98.86 Cr | ₹113.64 Cr | ₹117.00 Cr | ₹133.00 Cr | ₹138.00 Cr | ₹150.00 Cr |
Current assets, Non-current assets, CWIP, Others, Long-term debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹18.59 Cr | ₹-1.28 Cr | ₹-2.99 Cr | ₹10.30 Cr | ₹10.14 Cr | |
| Investing cash flow | — | ₹24.38 Cr | ₹44.10 L | ₹-1.70 Cr | ₹-5.94 Cr | ₹-12.41 Cr |
| — | ₹4.38 Cr | ₹1.35 Cr | ₹5.58 Cr | ₹-3.83 Cr | ₹2.20 Cr | |
| Capital expenditure | ₹-2.88 Cr | ₹-2.20 Cr | ₹-1.04 Cr | ₹-72.00 L | ₹-5.20 Cr | ₹-12.41 Cr |
| End cash position | — | — | ₹70.58 L | ₹1.59 Cr | ₹1.47 Cr | ₹1.40 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Nov 21–Dec 21(2Q) | Mar 22 | Jun 22–Dec 22(3Q) | Mar 23–Dec 23(4Q) | Mar 24–Jun 24(3Q) | Sep 24 | Dec 24–Sep 25(4Q) | Dec 25 | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 49.38% | 48.05% | 48.06% | 50.03% | 50.04% | 45.28% | 45.44% | 44.80% | 39.06% | 37.71% |
| Public | 50.62% | 51.95% | 51.94% | 49.97% | 49.96% | 54.72% | 54.56% | 55.20% | 60.94% | 62.29% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.49 L Cr | ₹9,410.5 | 84.7 | 14.85 | 15.3% | 0.00 | +12.3% | +51.8% |
| Torrent Pharmaceuticals Limited | ₹1.84 L Cr | ₹4,970 | 77.5 | 21.95 | 25.8% | 1.79 | +21.5% | +36.9% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹691.45 | 179.0 | 13.55 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,161 | 25.8 | 4.27 | 18.6% | 0.46 | +18.4% | +11.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,006.5 | 99.3 | 20.57 | 16.8% | 0.48 | +22.0% | +122.0% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Manipal Health Enterprises Limited | ₹99,047.90 Cr | ₹746.1 | 152.1 | 11.75 | 7.8% | 1.53 | +18.0% | — |
| Dr. Reddy's Laboratories Limited | ₹98,709.15 Cr | ₹1,198.3 | 29.8 | 2.62 | 11.4% | 0.21 | +3.2% | -9.3% |
| Aarey Drugs & Pharmaceuticals Limited | ₹337.55 Cr | ₹102.52 | 78.4 | 2.24 | 2.6% | 0.33 | -0.3% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 24
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.